Blurbs

BTIG Thinks Nuvation Bio’s Stock is Going to Recover

In a report issued on February 28, Kaveri Pohlman from BTIG assigned a Buy rating to Nuvation Bio (NUVBResearch Report), with a price target of $16.00. The company’s shares closed last Wednesday at $5.40, close to its 52-week low of $4.46.

According to TipRanks.com, Pohlman has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -31.4% and a 12.1% success rate. Pohlman covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Oncternal Therapeutics, and Mersana Therapeutics.

Currently, the analyst consensus on Nuvation Bio is a Moderate Buy with an average price target of $16.00.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $15.23 and a one-year low of $4.46. Currently, Nuvation Bio has an average volume of 1.14M.

Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NUVB in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Panacea Acquisition Corp is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

Read More on NUVB:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More